Free Trial
NASDAQ:EFTR

eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis

$1.17
0.00 (0.00%)
(As of 06/21/2024 ET)
Today's Range
$1.14
$1.32
50-Day Range
$1.16
$2.25
52-Week Range
$1.14
$22.50
Volume
175,418 shs
Average Volume
84,170 shs
Market Capitalization
$5.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00

eFFECTOR Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,951.3% Upside
$24.00 Price Target
Short Interest
Healthy
2.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.63) to ($2.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.76 out of 5 stars

EFTR stock logo

About eFFECTOR Therapeutics Stock (NASDAQ:EFTR)

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

EFTR Stock Price History

EFTR Stock News Headlines

The asset beating inflation by 4x
Central Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Retirement Protection Kit, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.
The asset beating inflation by 4x
Central Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Retirement Protection Kit, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.
See More Headlines
Receive EFTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
6/22/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EFTR
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.00
High Stock Price Target
$24.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+1,951.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-35,810,000.00
Pretax Margin
-5,332.49%

Debt

Sales & Book Value

Annual Sales
$3.55 million
Book Value
($1.94) per share

Miscellaneous

Free Float
4,483,000
Market Cap
$5.50 million
Optionable
Optionable
Beta
0.83
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Stephen T. Worland Ph.D. (Age 66)
    CEO, President & Director
    Comp: $873.96k
  • Mr. Michael Byrnes M.B.A. (Age 47)
    Chief Financial Officer
    Comp: $654.82k
  • Dr. Douglas Warner M.D. (Age 52)
    Chief Medical Officer
    Comp: $660.16k
  • Dr. Davide Ruggero Ph.D.
    Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Kevan M. Shokat Ph.D.
    Co-Founder and Member of Clinical & Scientific Advisory Board

EFTR Stock Analysis - Frequently Asked Questions

Should I buy or sell eFFECTOR Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for eFFECTOR Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EFTR shares.
View EFTR analyst ratings
or view top-rated stocks.

What is eFFECTOR Therapeutics' stock price target for 2024?

1 analysts have issued 1 year price objectives for eFFECTOR Therapeutics' stock. Their EFTR share price targets range from $24.00 to $24.00. On average, they expect the company's share price to reach $24.00 in the next year. This suggests a possible upside of 1,951.3% from the stock's current price.
View analysts price targets for EFTR
or view top-rated stocks among Wall Street analysts.

How have EFTR shares performed in 2024?

eFFECTOR Therapeutics' stock was trading at $11.6850 at the start of the year. Since then, EFTR shares have decreased by 90.0% and is now trading at $1.17.
View the best growth stocks for 2024 here
.

Are investors shorting eFFECTOR Therapeutics?

eFFECTOR Therapeutics saw a decline in short interest during the month of May. As of May 31st, there was short interest totaling 94,700 shares, a decline of 14.5% from the May 15th total of 110,700 shares. Based on an average daily volume of 352,200 shares, the short-interest ratio is presently 0.3 days. Currently, 2.4% of the shares of the company are sold short.
View eFFECTOR Therapeutics' Short Interest
.

When is eFFECTOR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our EFTR earnings forecast
.

How were eFFECTOR Therapeutics' earnings last quarter?

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) posted its earnings results on Thursday, May, 9th. The company reported ($2.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.17) by $0.01.

When did eFFECTOR Therapeutics' stock split?

eFFECTOR Therapeutics's stock reverse split on Friday, January 12th 2024. The 1-25 reverse split was announced on Friday, January 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are eFFECTOR Therapeutics' major shareholders?

eFFECTOR Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Carlyle Group Inc. (5.23%), StemPoint Capital LP (3.60%) and Blackstone Inc. (1.42%). Insiders that own company stock include Brian M Jr Gallagher, Christopher B Ehrlich, Jonathan D Root, Michael Byrnes, Presidio Management Group X Ll, Sr One Capital Management, Llc and Stephen T Worland.
View institutional ownership trends
.

How do I buy shares of eFFECTOR Therapeutics?

Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EFTR) was last updated on 6/22/2024 by MarketBeat.com Staff

From Our Partners